JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90) bottles, Rx only, Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA and Eli Lilly and Company Indianapolis, IN 46285 USA
Published March 29, 2023 · Recall initiated: March 9, 2023
Summary
FDA records drug Class II recall D-0468-2023, published March 29, 2023 and initiated March 9, 2023. Recalling firm: Boehringer Ingelheim Pharmaceuticals, Inc.; Status: Terminated; Reported quantity: 69,375 bottles; Lot: Lot #: a) and b) E61835, exp. date JUN 2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Labeling: Label Mix-up
What to do
Voluntary: Firm initiated · Letter
Get an email if JARDIANCE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- JARDIANCE
- Manufacturer
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Distributor
- Product was distributed nationwide within the United States and PR
- Lot
- Lot #: a) and b) E61835, exp. date JUN 2025
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAJardiance (empagliflozin tablets), 25 mg, 30 tablets (3 blister cards with 10 tablets each), Rx only,January 3, 2024
- FDADaytrana (methylphenidate transdermal system) CII, 10mg, 30-count carton, Rx only, Manufactured for NovenMarch 29, 2023
- FDADaytrana (methylphenidate transdermal system) CII, 15 mg, 30-count carton, Rx only, Manufactured for NovenMarch 29, 2023
- FDAPatient Side Cart, REF: 380620, with instrument arms, used as part of the da Vinci X Surgical System, REF:March 22, 2023
- FDACanton Dry Noodle, packaged in 30lb. corrugated (cardboard) boxes.March 22, 2023
- FDAWonton wrappers, 4" x 4" and 3.5" x 3.5", packaged in 30lb. corrugated (cardboard) boxes. Product is soldMarch 22, 2023
Questions about this recall
Was JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90) bottles, Rx only, Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA and Eli Lilly and Company Indianapolis, IN 46285 USA recalled?
Yes. FDA published recall D-0468-2023 on March 29, 2023. Reported hazard: Labeling: Label Mix-up
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: JARDIANCE.